- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04541329
Predicting Inflammatory Skin Disease Response to IL-23 Blockade
June 2, 2022 updated by: University of California, San Francisco
This study examines the effect of IL-23 blockade with Tildrakizumab on the immune cells of psoriatic skin lesions.
Study Overview
Detailed Description
This is a one-arm, open-label study to examine the effect of Tildrakizumab.
Tildrakizumab is a FDA-approved medication for the treatment of cutaneous psoriasis.
This study will examine how Tildrakizumab affects immune cells within psoriatic skin lesions.
Fifteen subjects with moderate to severe psoriasis will be enrolled.
Biopsy samples will be collected and undergo molecular profiling to correlate profiles with and to predict Tildrakizumab treatment response.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jeffrey Cheng, MD, PhD
- Phone Number: 415-575-0524
- Email: rashes@ucsf.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94158
- Recruiting
- University of California, San Francisco
-
Contact:
- Jeffrey Cheng, MD, PhD
- Email: rashes@ucsf.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female ≥18 years of age at clinic visit.
- Documentation of moderate-severe psoriasis or atypical psoriasis.
- Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
Exclusion Criteria:
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
- Tuberculosis, active serious infection, active systemic malignancy,
- Received a systemic medication for psoriasis within 3 months of study screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Tildrakizumab treatment
|
IL-23 inhibitor
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Psoriasis Area and Severity Index (PASI) Score from Baseline to 3 months
Time Frame: baseline and 3 months
|
Change in severity and extent of psoriasis (calculated by Psoriasis Area and Severity Index (PASI) score); scale range of 0 to 72, 72 being maximal disease.
|
baseline and 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 16, 2020
Primary Completion (ANTICIPATED)
September 9, 2024
Study Completion (ANTICIPATED)
September 9, 2024
Study Registration Dates
First Submitted
September 1, 2020
First Submitted That Met QC Criteria
September 1, 2020
First Posted (ACTUAL)
September 9, 2020
Study Record Updates
Last Update Posted (ACTUAL)
June 6, 2022
Last Update Submitted That Met QC Criteria
June 2, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-29813
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis Vulgaris
-
LEO PharmaCompletedPlaque Psoriasis | Psoriasis VulgarisGermany
-
SoligenixRecruitingPsoriasis | Plaque Psoriasis | Psoriasis VulgarisUnited States
-
LEO PharmaTerminatedPsoriasis | Plaque Psoriasis | Psoriasis VulgarisBelgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
-
PRCL Research Inc.CompletedPlaque Psoriasis | Psoriasis VulgarisCanada, Slovakia, Ukraine
-
Chinese University of Hong KongNot yet recruitingPsoriasis Vulgaris
-
University Hospital, GhentRecruitingPsoriasis VulgarisBelgium
-
University Hospital, GhentRecruitingPsoriasis VulgarisBelgium
-
University of California, San FranciscoNovartis Pharmaceuticals; National Psoriasis FoundationRecruitingPsoriasis VulgarisUnited States
-
Centre for Human Drug Research, NetherlandsJanssen PharmaceuticalsRecruiting
-
University Hospital, GhentKU Leuven; University GhentRecruitingPsoriasis VulgarisBelgium
Clinical Trials on Tildrakizumab
-
Almirall, S.A.Active, not recruitingPlaque PsoriasisGermany, Austria, Italy, Netherlands
-
Marcelo F. Di Carli, MD, FACCRecruiting
-
Almirall, S.A.RecruitingGenital PsoriasisAustria
-
Sun Pharmaceutical Industries LimitedCompleted
-
Sun Pharmaceutical Industries LimitedActive, not recruitingChronic Plaque Psoriasis | Moderate to Severe Nail PsoriasisUnited States, Australia
-
Almirall, S.A.Recruiting
-
Merck Sharp & Dohme LLCCompleted
-
Almirall, S.A.TerminatedPlaque PsoriasisPoland
-
Medical College of WisconsinActive, not recruitingHematologic MalignanciesUnited States
-
Sun Pharmaceutical Industries LimitedRecruitingSafety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With TildrakizumabPregnancy RelatedUnited States